Hisao Nagoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hisao Nagoshi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Junya Kuroda
Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan
3 shared publications - Masafumi Taniwaki
Department of Hematology and Oncology, Kyoto Prefectural University of Medicine
2 shared publications - Tomohiko Taki
Department of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan
2 shared publications Tsutomu Kobayashi
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan
2 shared publicationsAkihito Hiramatsu
Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan
1 shared publicationAkiko Yamazaki
Department of Dermatology; Kyoto Prefectural University of Medicine; Kyoto Japan
1 shared publication
Latest Publications
- 22 September 2015
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 54 (12) , 788-795
Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance
The deleted in colorectal carcinoma (DCC) gene at 18q21 encodes a netrin-1 receptor, a tumor suppressor that prevents cell growth. While allele loss or decreased expression of DCC has been associated with the progression of solid tumors and hematologic malignancies, including leukemias and malignant lymphomas, its involvement has not been evaluated in multiple myeloma (MM), a plasma cell malignancy characterized by complex and heterogenous molecular abnormalities. We here show that 10 of 11 human myeloma-derived cell lines (HMCLs) expressed non-translated aberrant DCC transcriptional variants, in which exon 2 fuses with intron 1 instead of exon 1 (mt.DCC). Among them, two co-expressed wild type transcripts (wt.DCC), while eight co-expressed the splicing variant (sv.DCC) lacking exon 1. The remaining HMCL expressed only sv.DCC. In addition, analyses revealed that there were two types of mt.DCC that differed in their fusion of intron 1 with exon 2. In patient-derived samples from 30 MM and 8 monoclonal gammopathy of undetermined significance (MGUS) patients, wt.DCC was expressed in 53% of MM, but not in MGUS, while 23% of MM and 75% of MGUS expressed only sv.DCC. Considering that 25% of MGUS, 57% of MM, and 91% HMCLs expressed mt.DCC, our results suggest that the acquisition of mt.DCC might be a secondary genetic change in plasma cell dyscrasia.
- 22 September 2015
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 54 (12) , 788-795
Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance
The deleted in colorectal carcinoma (DCC) gene at 18q21 encodes a netrin-1 receptor, a tumor suppressor that prevents cell growth. While allele loss or decreased expression of DCC has been associated with the progression of solid tumors and hematologic malignancies, including leukemias and malignant lymphomas, its involvement has not been evaluated in multiple myeloma (MM), a plasma cell malignancy characterized by complex and heterogenous molecular abnormalities. We here show that 10 of 11 human myeloma-derived cell lines (HMCLs) expressed non-translated aberrant DCC transcriptional variants, in which exon 2 fuses with intron 1 instead of exon 1 (mt.DCC). Among them, two co-expressed wild type transcripts (wt.DCC), while eight co-expressed the splicing variant (sv.DCC) lacking exon 1. The remaining HMCL expressed only sv.DCC. In addition, analyses revealed that there were two types of mt.DCC that differed in their fusion of intron 1 with exon 2. In patient-derived samples from 30 MM and 8 monoclonal gammopathy of undetermined significance (MGUS) patients, wt.DCC was expressed in 53% of MM, but not in MGUS, while 23% of MM and 75% of MGUS expressed only sv.DCC. Considering that 25% of MGUS, 57% of MM, and 91% HMCLs expressed mt.DCC, our results suggest that the acquisition of mt.DCC might be a secondary genetic change in plasma cell dyscrasia.
- 3 December 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (1) , 100-101
Disseminated mucormycosis due toRhizopus oryzaediagnosed by skin biopsy
- 3 December 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 42 (1) , 100-101
Disseminated mucormycosis due toRhizopus oryzaediagnosed by skin biopsy
- Open Access
- 23 September 2014
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 7 (1) , 68
8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia
The pathogenetic roles of 8q24 amplified segments in leukemic cells with double minute chromosomes remain to be verified. Through comprehensive molecular analyses of 8q24 amplicons in leukemic cells from an acute myelogenous leukemia (AML) patient and AML-derived cell line HL60 cells, we identified two novel fusion genes between NSMCE2 and long noncoding RNAs (lncRNAs), namely, PVT1-NSMCE2 and BF104016-NSMCE2. Our study suggests that 8q24 amplicons are associated with the emergence of aberrant chimeric genes between NSMCE2 and oncogenic lncRNAs, and also implicate that the chimeric genes involving lncRNAs potentially possess as-yet-unknown oncogenic functional roles.
- 23 September 2014
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 7 (1) , 68
Open Access8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia
The pathogenetic roles of 8q24 amplified segments in leukemic cells with double minute chromosomes remain to be verified. Through comprehensive molecular analyses of 8q24 amplicons in leukemic cells from an acute myelogenous leukemia (AML) patient and AML-derived cell line HL60 cells, we identified two novel fusion genes between NSMCE2 and long noncoding RNAs (lncRNAs), namely, PVT1-NSMCE2 and BF104016-NSMCE2. Our study suggests that 8q24 amplicons are associated with the emergence of aberrant chimeric genes between NSMCE2 and oncogenic lncRNAs, and also implicate that the chimeric genes involving lncRNAs potentially possess as-yet-unknown oncogenic functional roles.
- Open Access
- 2 October 2011
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (1) , 42-53
Establishment of a novel human myeloid leukemia cell line, AMU-AML1, carrying t(12;22)(p13;q11) without chimeric MN1-TEL and with high expression of MN1
- 2 October 2011
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 51 (1) , 42-53
Open AccessEstablishment of a novel human myeloid leukemia cell line, AMU-AML1, carrying t(12;22)(p13;q11) without chimeric MN1-TEL and with high expression of MN1